<DOC>
	<DOCNO>NCT00264537</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety golimumab , alone combination methotrexate , compare methotrexate alone rheumatoid arthritis subject previously treat methotrexate .</brief_summary>
	<brief_title>A Study Safety Efficacy Golimumab Subjects With Rheumatoid Arthritis That Are Methotrexate-naive</brief_title>
	<detailed_description>Golimumab fully human protein ( antibody ) bind tumor necrosis factor ( TNFa ) . TNFa increase patient rheumatoid arthritis ( RA ) , play major role cause joint pain , swell , damage RA . Other market drug target TNFa ( anti-TNFa drug ) show effective reducing symptom , sign , joint damage RA , limitation respect safety ease use . This randomized , double-blind , placebo-controlled trial efficacy safety new anti-TNFa drug , golimumab , 2 dos , inject skin every 4 week , alone combination methotrexate , compare methotrexate alone , subject active RA previously treat methotrexate . The study hypothesis golimumab , alone combination methotrexate , effective treatment RA methotrexate alone , measured American College Rheumatology ( ACR ) response criterion change baseline van der Heide Modified Sharp ( vdH-S ) score , without cause unacceptable significant adverse effect . The ACR response criterion design determine percentage subject achieve certain level improvement sign symptom rheumatoid arthritis . The vdH-S score measurement amount joint damage subject see x-ray . Other secondary measure effectiveness include Health Assessment Questionnaire ( HAQ ) , series question measure subject 's impairment physical function cause RA . Golimumab 50 mg 100 mg , placebo injection skin every 4 week Week52 . Methotrexate ( MTX ) placebo capsule give addition . At Week52 , subject MTX alone joint pain swell get golimumab 50mg , subject receive golimumab 4 year .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have diagnosis rheumatoid arthritis ( RA ) ( accord revise 1987 criterion ACR ) least 3 month prior first administration study agent Are methotrexate ( MTX ) naïve ( ie , receive 3 weekly dos MTX RA time ) Have active RA define persistent disease activity least 4 swollen 4 tender joint , time screen baseline , least 2 follow 4 criterion : ) Creactive protein ( CRP ) &gt; =1.5 mg/dL screen erythrocyte sedimentation rate ( ESR ) Westergren method &gt; = 28 mm first hour screen baseline , b ) Morning stiffness &gt; = 30 minute screen baseline , c ) Bone erosion xray and/or MRI prior first administration study agent , ) Anticyclic citrullinated peptide ( antiCCP ) antibodypositive rheumatoid factor ( RF ) positive screening If use oral corticosteroid , must stable dose equivalent &lt; = 10 mg prednisone/day least 2 week prior first administration study agent . Can inflammatory disease RA might confound evaluation benefit golimumab therapy No treatment diseasemodifying antirheumatic drug ( DMARDs ) /systemic immunosuppressives 4 week prior first administration study agent No prior treatment biologic antiTNF drug ( infliximab , etanercept , adalimumab ) No history , ongoing , chronic recurrent infectious disease No serious infection within 2 month prior first administration study agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Methotrexate Naïve</keyword>
	<keyword>subcutaneous injection</keyword>
</DOC>